SPARC

What does SPARC do?

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical firm focused on developing new drugs and delivery systems, with a market cap of Rs 5,332 Cr. As of March 2025, it reported net sales of 27 Cr and a net loss of 60 Cr.

Overview:<BR>Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems within the Pharmaceuticals & Biotechnology industry, categorized as a Mid Cap.<BR><BR>History:<BR>SPARC was incorporated on March 1, 2006, as an innovative and development company. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 27 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -60 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 5,332 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.23 <BR>Return on Equity: 157.88% <BR>Price to Book: -24.24<BR><BR>Contact Details:<BR>Address: Sun Pharma Advanced Res Centre, Akota Road Akota Vadodara Gujarat : 390020 <BR>Tel: 91-265-2330815/2339257 <BR>Email: secretarial@sparcmail.com <BR>Website: http://www.sparc.life

Has SPARC declared dividend?

No Dividend History Available

Who are the peers of the SPARC?

SPARC's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Supriya Lifesci, Innova Captab, Sequent Sciences, Hikal, and Unichem Labs. SPARC has the lowest 1-year return at -7.64%, while Supriya Lifesci leads with a return of 100.72%.

Peers: The peers of SPARC are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Supriya Lifesci., Innova Captab, Sequent Scien., Hikal, and Unichem Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Supriya Lifesci., and Hikal, while Average management risk is found at Innova Captab and Sequent Scien. Good management risk is present at Divi's Lab., Torrent Pharma, and Unichem Labs. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, SPARC, Supriya Lifesci., Sequent Scien., and Hikal. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Innova Captab, while below average capital structure is found at SPARC and Sequent Scien., and average capital structure is observed at Hikal.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 100.72%, while SPARC has the lowest at -7.64%. SPARC's 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for SPARC, Sun Pharma.Inds., Torrent Pharma, and Sequent Scien.

Who are in the management team of SPARC?

As of March 2023, the management team of SPARC includes T Rajamannar, Sudhir V Valia, Bhavna Doshi, Ferzaan Engineer, Robert Spiegel, and Dilip S Shanghvi as Chairman (Non-Executive). They are responsible for the company's governance and strategic direction.

As of March 2023, the management team of SPARC includes the following individuals:<BR><BR>1. T Rajamannar - Director<BR>2. Sudhir V Valia - Director<BR>3. Bhavna Doshi - Independent Director<BR>4. Ferzaan Engineer - Independent Director<BR>5. Robert Spiegel - Independent Director<BR>6. Dilip S Shanghvi - Chairman (Non-Executive)<BR><BR>These members play key roles in the governance and strategic direction of the company.

Who are the top shareholders of the SPARC?

The top shareholders of SPARC include Shanghvi Finance Private Ltd with 42.28%, followed by individual investors at 18.99%, and the Sun Pharmaceutical Industries Key Employees Benefit Trust at 3.18%. Mutual funds and foreign institutional investors hold 1.01% and 1.45%, respectively, with no pledged promoter holdings.

The top shareholders of SPARC include the promoters, with Shanghvi Finance Private Ltd holding the largest stake at 42.28%. There are no pledged promoter holdings. In addition, mutual funds hold a total of 1.01% through 10 schemes, while foreign institutional investors (FIIs) account for 1.45% through 31 different FIIs. The highest public shareholder is the Sun Pharmaceutical Industries Key Employees Benefit Trust, which holds 3.18%. Individual investors collectively own 18.99% of the company.

How big is SPARC?

As of 24th July, Sun Pharma Advanced Research Company Ltd has a market capitalization of 5,061.00 Cr, with recent net sales of 71.77 Cr and a net profit loss of 342.51 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Sun Pharma Advanced Research Company Ltd has a market capitalization of 5,061.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 71.77 Cr, while the sum of Net Profit for the same period shows a loss of 342.51 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds stand at a loss of 216.95 Cr, and Total Assets are valued at 333.22 Cr.

How has been the historical performance of SPARC?

SPARC has experienced a significant decline in financial performance over the past three years, with net sales dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025, and operating losses worsening from -203.18 crore to -321.35 crore in the same period. Overall, the company's financial metrics indicate ongoing operational challenges.

Answer:<BR>The historical performance of SPARC shows a significant decline in key financial metrics over the past three years, particularly in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>SPARC's net sales decreased from 238.78 crore in March 2023 to 75.55 crore in March 2024, and further down to 71.77 crore in March 2025. The total operating income followed a similar trend, dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025. The company faced substantial operating losses, with operating profit (PBDIT) worsening from -203.18 crore in March 2023 to -321.35 crore in March 2025. Profit before tax also reflected this negative trend, moving from -222.58 crore in March 2023 to -342.78 crore in March 2025. Consequently, profit after tax showed a similar decline, falling from -222.58 crore in March 2023 to -342.51 crore in March 2025. The company's total liabilities decreased from 830.13 crore in March 2023 to 333.22 crore in March 2025, while total assets also fell from 830.13 crore to 333.22 crore in the same period. Cash flow from operating activities remained negative, with a cash outflow of -360 crore in March 2025 compared to -429 crore in March 2024. Overall, SPARC's financial performance has deteriorated significantly over the years, indicating ongoing challenges in its operations.

How has been the historical performance of SPARC?

SPARC has faced significant financial challenges over the past three years, with net sales declining from 238.78 Cr in March 2023 to 71.77 Cr in March 2025, and increasing losses reflected in negative operating profit and profit after tax. Despite some cost control efforts, the company has seen a substantial decrease in total assets and liabilities, alongside persistent negative cash flow from operating activities.

Answer:<BR>The historical performance of SPARC shows significant challenges over the past three years, particularly in terms of revenue and profitability.<BR><BR>Breakdown:<BR>SPARC's net sales have declined sharply from 238.78 Cr in March 2023 to 75.55 Cr in March 2024, and further to 71.77 Cr in March 2025. Total operating income followed a similar trend, decreasing from 238.78 Cr in March 2023 to 71.77 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased from 452.84 Cr in March 2023 to 394.91 Cr in March 2025, indicating some cost control efforts. However, operating profit (PBDIT) remained negative, worsening from -203.18 Cr in March 2023 to -321.35 Cr in March 2025. The profit before tax also showed a negative trend, moving from -222.58 Cr in March 2023 to -342.78 Cr in March 2025. Consequently, the profit after tax reflected similar losses, with figures of -222.58 Cr, -387.21 Cr, and -342.51 Cr for the respective years. The company's total liabilities decreased from 830.13 Cr in March 2023 to 333.22 Cr in March 2025, while total assets also fell from 830.13 Cr to 333.22 Cr in the same period. Cash flow from operating activities remained negative, with -360.00 Cr in March 2025, although cash flow from investing activities turned positive at 157.00 Cr. Overall, SPARC's financial performance indicates a trend of declining sales and increasing losses, alongside a significant reduction in total assets and liabilities.

Is SPARC technically bullish or bearish?

As of November 27, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish sentiment, despite mixed signals from the MACD and KST, suggesting a cautious approach.

As of 27 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the weekly Bollinger Bands also showing a mildly bearish outlook. The MACD on the weekly is mildly bullish, but the monthly remains bearish, creating a mixed signal. The KST aligns with the weekly MACD, being mildly bullish, while the OBV is mildly bearish on the weekly timeframe. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest a cautious approach.

When is the next results date for Sun Pharma Advanced Research Company Ltd?

The next results date for Sun Pharma Advanced Research Company Ltd is 09 February 2026.

The next results date for Sun Pharma Advanced Research Company Ltd is scheduled for 09 February 2026.

Are Sun Pharma Advanced Research Company Ltd latest results good or bad?

Sun Pharma Advanced Research Company Ltd's latest results are poor, showing a net loss of ₹80.42 crores and a 43.33% decline in revenue year-on-year, with a negative book value per share and high operational costs. Investors should be cautious due to the company's deteriorating financial health and rising debt levels.

The latest results for Sun Pharma Advanced Research Company Ltd (SPARC) indicate a challenging financial situation. In Q3 FY26, the company reported a net loss of ₹80.42 crores, which reflects a slight increase in losses of 1.14% year-on-year. Revenue also declined significantly, down 43.33% year-on-year, with net sales recorded at just ₹8.45 crores. <BR><BR>The operating margin was reported at an alarming -670.30%, indicating that the company's operational costs are vastly outpacing its revenues. Furthermore, the book value per share has turned negative at ₹-6.68, highlighting a severe equity erosion. <BR><BR>The financial performance illustrates a company struggling with a high cost structure, particularly with employee expenses that far exceed revenues. The situation is compounded by rising debt levels, with interest costs now at ₹8.78 crores per quarter, adding to the financial strain.<BR><BR>Overall, the results can be characterized as poor, with significant challenges ahead for SPARC in terms of achieving profitability and sustaining operations. Investors should exercise caution given the company's deteriorating financial health and lack of a clear path to recovery.

Should I buy, sell or hold Sun Pharma Advanced Research Company Ltd?

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 17-Mar, Sun Pharma Advanced Research Company Ltd's stock price is slightly rising at Rs 114.80, indicating a potential trend reversal after recent declines. However, the stock has significantly underperformed over the past month and year-to-date, suggesting a weak long-term outlook despite increased investor interest.

As of 17-Mar, Sun Pharma Advanced Research Company Ltd's stock price is rising slightly, with a current price of Rs 114.80, reflecting a change of 0.6 (0.53%) upward. This increase comes after three consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 0.25% today, which may contribute to the positive sentiment among investors.<BR><BR>However, it is important to note that the stock has been underperforming over longer periods, with a significant decline of -14.49% over the past month and -14.62% year-to-date. The stock is also close to its 52-week low, just 2.7% away from Rs 111.7. Despite the current rise, the overall performance metrics indicate a weak long-term outlook, with negative growth in net sales and operating profit over the last five years.<BR><BR>Investor participation has increased, with a delivery volume of 13.21 lacs on 16 March, which is a 16.06% rise compared to the five-day average. This could suggest a growing interest in the stock, despite its underlying financial challenges, including a negative book value and poor ability to service debt.<BR><BR>In summary, while there is a slight rise in the stock price today, the broader context of declining sales, negative results over recent quarters, and overall underperformance in the market suggests that the stock remains in a precarious position.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 18-Mar, Sun Pharma Advanced Research Company Ltd's stock price is currently at 120.20, reflecting a short-term rise of 4.7%. However, it has declined by 3.99% over the past week and 9.15% over the past month, indicating a weaker long-term performance despite recent gains.

As of 18-Mar, Sun Pharma Advanced Research Company Ltd's stock price is rising, currently at 120.20, reflecting a change of 5.4 (4.7%) upward. This increase can be attributed to the stock outperforming its sector by 4.43% today and experiencing consecutive gains over the last two days, with a total return of 5.25% during this period. Additionally, the stock reached an intraday high of Rs 123.5, marking a rise of 7.58%.<BR><BR>However, it is important to note that despite this short-term rise, the stock has shown a negative performance over longer periods. For instance, it has declined by 3.99% over the past week and 9.15% over the past month. Furthermore, the stock is trading below its moving averages across various time frames, indicating a generally weaker trend. The delivery volume has also decreased by 6.5% compared to the five-day average, suggesting a decline in investor participation.<BR><BR>Overall, while the stock is currently experiencing a rise, it is essential to consider the broader context of its long-term performance, which has been characterized by significant declines in net sales and negative financial results in recent quarters.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 19-Mar, Sun Pharma Advanced Research Company Ltd's stock is at 115.20, down 4.16%, and has significantly underperformed the Sensex. The company faces weak financial results, including a 43.29% drop in net sales and negative profit, contributing to its bearish trend.

As of 19-Mar, Sun Pharma Advanced Research Company Ltd's stock price is falling, currently at 115.20, which reflects a decrease of 5.0 (-4.16%). The stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of 5.65% versus the Sensex's 2.40% drop, and a 1-month decline of 12.06% compared to the Sensex's 10.05% decline. <BR><BR>The stock is also close to its 52-week low, just 3.04% away from Rs 111.7, indicating a weak performance trend. Today's performance shows that the stock has underperformed its sector by 2.01%. Additionally, the stock has fallen after two consecutive days of gains, suggesting a reversal in trend. It reached an intraday low of Rs 114.95, down 4.37%, and is trading below all its moving averages, which further indicates a bearish trend.<BR><BR>Financially, the company has reported very negative results, with a significant fall in net sales of 43.29% and negative results for the last three consecutive quarters. The latest six months show net sales at Rs 16.31 crore, down 41.27%, and a negative profit after tax of Rs -143.91 crore. The company's ability to service its debt is also weak, as indicated by a poor EBIT to interest ratio of -141.22. <BR><BR>Overall, the combination of poor financial performance, negative growth rates, and underperformance compared to both the sector and broader market indices contributes to the stock's decline.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 20-Mar, the stock price of Sun Pharma Advanced Research Company Ltd is slightly rising at 115.65, but it faces significant long-term challenges, including a -19.97% return over the past year and negative financial results. The stock's performance indicates a bearish outlook due to declining investor participation and weak fundamentals.

As of 20-Mar, the stock price of Sun Pharma Advanced Research Company Ltd is experiencing a slight rise, currently at 115.65, with a change of 0.45 (0.39%) upward. However, this increase occurs against a backdrop of significant long-term challenges. Over the past year, the stock has generated a return of -19.97%, indicating a substantial decline in value. The company has reported negative results for the last three consecutive quarters, with net sales falling by 43.29% and a negative profit after tax of Rs -143.91 crore, which has grown at -41.27%.<BR><BR>Moreover, the stock is trading below its moving averages across various time frames, suggesting a downward trend. It is also close to its 52-week low, being only 3.42% away from Rs 111.7. The delivery volume has seen a drastic decline of 80.79% compared to the 5-day average, indicating falling investor participation. Additionally, the company has a negative book value and weak long-term fundamental strength, with poor growth rates in net sales and operating profit over the last five years.<BR><BR>In summary, while there is a minor uptick in the stock price today, the overall performance and financial health of Sun Pharma Advanced Research Company Ltd indicate significant underlying weaknesses, leading to a generally bearish outlook.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 23-Mar, Sun Pharma Advanced Research Company Ltd's stock is at Rs. 108.80, down 5.92%, and has reached a 52-week low. The company faces significant financial challenges, including a 43.29% drop in net sales and negative results for three consecutive quarters, contributing to a bearish market sentiment.

As of 23-Mar, Sun Pharma Advanced Research Company Ltd's stock price is falling, currently at Rs. 108.80, which reflects a decrease of Rs. 6.85 or 5.92%. The stock has recently hit a new 52-week low of Rs. 108.2 and has underperformed its sector by 2.35% today. Over the past week, the stock has declined by 4.73%, and its performance over the last month shows a significant drop of 14.83%. <BR><BR>The company's financial health is concerning, with a negative book value and weak long-term fundamental strength. Net sales have decreased at an alarming rate of 43.29%, and the company has reported negative results for three consecutive quarters. The latest six-month profit after tax (PAT) stands at Rs. -143.91 crore, reflecting a decline of 41.27%. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend.<BR><BR>Investor participation has also diminished, with delivery volume dropping by 81.85% compared to the five-day average, suggesting a lack of confidence among investors. The overall performance of the pharmaceuticals and drugs sector has declined by 3.58%, further contributing to the negative sentiment surrounding the stock. Given these factors, including poor sales growth and high debt servicing challenges, the stock's decline appears to be driven by a combination of weak financial performance and broader market trends.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 24-Mar, Sun Pharma Advanced Research Company Ltd's stock is rising to Rs 112.00, up 2.94%, but faces significant long-term challenges with a year-to-date decline of 16.70% and negative financial results, indicating a concerning investment outlook.

As of 24-Mar, Sun Pharma Advanced Research Company Ltd's stock price is rising, currently at Rs 112.00, reflecting an increase of 3.2 points or 2.94%. This rise is notable as the stock has outperformed its sector by 1.82% today and reached an intraday high of Rs 113.95, which is a 4.73% increase. However, despite this daily performance, the stock has been under pressure over longer periods, with a year-to-date decline of 16.70% and a one-year drop of 28.18%.<BR><BR>The stock is currently trading close to its 52-week low, just 3.39% above Rs 108.2. Additionally, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend. There has also been a significant drop in investor participation, with delivery volume falling by 61.25% compared to the five-day average, suggesting reduced interest from investors.<BR><BR>Moreover, the company faces serious financial challenges, including a negative book value and a weak long-term fundamental strength. The net sales have declined sharply by 43.29%, and the company has reported negative results for three consecutive quarters. The latest PAT stands at Rs -143.91 crore, reflecting a 41.27% decline. These factors contribute to a risky investment profile, as the stock has generated negative returns over the past year while profits have paradoxically increased.<BR><BR>In summary, while the stock is experiencing a short-term rise, the underlying financial difficulties and poor long-term performance suggest that this may not be sustainable, and the overall outlook remains concerning.

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 25-Mar, Sun Pharma Advanced Research Company Ltd's stock price is rising to Rs 131.75, reflecting a 17.69% increase. Despite short-term gains, the company faces long-term challenges, including negative results for three consecutive quarters and a significant decline in net sales.

As of 25-Mar, Sun Pharma Advanced Research Company Ltd's stock price is rising, currently at Rs 131.75, reflecting a change of Rs 19.8 or 17.69% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 15.8% today and has experienced consecutive gains over the last two days, accumulating a total return of 21.09% during this period. Additionally, the stock reached an intraday high of Rs 133.5, indicating strong trading activity.<BR><BR>In the short term, the stock has shown resilience, with a 9.61% increase over the past week, contrasting sharply with the Sensex, which has declined by 1.87%. However, it is essential to note that despite this recent rise, the company has faced significant challenges in its long-term performance. The company has reported negative results for the last three consecutive quarters, with a drastic fall in net sales of 43.29% and a negative book value, indicating weak long-term fundamental strength.<BR><BR>While the current price increase may attract attention, the underlying financial health of the company remains concerning, as evidenced by its poor EBIT to interest ratio and declining net sales over the past five years. Therefore, while the stock is rising in the short term, it is essential to consider the broader context of its financial performance and market position.

Which are the latest news on SPARC?